Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | UNG | P13051 | 2/20 | 0.41 |
| ▸ | CASR | P41180 | 2/20 | 0.41 |
| ▸ | ACACB | O00763 | 4/20 | 0.38 |
| ▸ | ACACA | Q13085 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mavacamten SCHEMBL16320785 | 0.79 | CYP3A4 (1.00) | CYP3A4CYP2B6SMN1; SMN2HTT | |
| Mavacamten SCHEMBL16322996 | 0.79 | CYP3A4 (1.00) | CYP3A4CYP2B6SMN1; SMN2HTT | |
| SCHEMBL16364785 | 0.78 | CYP3A4 (0.63) | CYP3A4CYP2B6SMN1; SMN2HTT | |
| SCHEMBL22442420 | 0.73 | CYP3A4 (0.58) | CYP3A4CYP2B6SMN1; SMN2HTT | |
| SCHEMBL16320678 | 0.73 | CYP3A4 (0.69) | CYP3A4CYP2B6SMN1; SMN2HTT | |
| SCHEMBL31686185 | 0.71 | CYP3A4 (0.74) | CYP3A4CYP2B6SMN1; SMN2HTT | |
| SCHEMBL16320781 | 0.71 | CYP3A4 (0.69) | CYP3A4CYP2B6SMN1; SMN2HTT | |
| SCHEMBL16320771 | 0.70 | CYP3A4 (0.72) | CYP3A4CYP2B6SMN1; SMN2HTT | |
| SCHEMBL16324266 | 0.70 | CYP3A4 (0.60) | CYP3A4CYP2B6SMN1; SMN2HTTACACB | |
| SCHEMBL16324269 | 0.70 | CYP3A4 (0.60) | CYP3A4CYP2B6SMN1; SMN2HTTACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281626-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2017-10-05 | — | — | US | disclosed |
| US-9585883-B2 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160030428-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2016-02-04 | — | — | US | disclosed |
| US-9181200-B2 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140378464-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2014-12-25 | — | — | US | disclosed |
| WO-2014205223-A1 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | MyoKardia, Inc. (US) | 2014-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378464-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | CYP3A4 2600/4885CYP2B6 1992/4885SMN1; SMN2 1177/4885 |
| US-20160030428-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | CYP3A4 2600/4885CYP2B6 1992/4885SMN1; SMN2 1177/4885 |
| US-20170281626-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | CYP3A4 2600/4885CYP2B6 1992/4885SMN1; SMN2 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.